Abstract
Patients with psoriasis have got more frequent other immune mediated diseases (PsA, RA, AS, UC,SM) but also the diseases of metabolic syndrom. Psoriasis is considered to be an independent risk factor for cardiovascular diseases.
The cause of these comorbidities might be in their similar genetic background as well as in the presence of immune mediated inflammation – with the key importace of the increased Th1/Th17 response that may play a role also in atherosclerotic changes. Early, effective nad long-term therapy of psoriasis could prevent the development of metabolic comorbidities.
Drugs as statins, nicotinic acid agonists or PPAR agonists are perspective for treatmnt of psoriartic comorbidities because of their immonomodulatory and anti-inflammatory effects.